Befotertinib - a viable alternative in EGFR-mutant advanced NSCLC?
Mené sur 362 patients atteints d'un cancer du poumon non à petites cellules de stade localement avancé ou métastatique et présentant des mutations au niveau du gène EGFR, cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du béfotertinib (un inhibiteur de tyrosine kinase de l'EGFR de 3ème génération) et de l'icotinib en traitement de première ligne
The treatment landscape of epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer (NSCLC) has evolved rapidly, and osimertinib, a third-generation EGFR tyrosine-kinase inhibitor (TKI), has become the standard preferred treatment option in first-line settings based on its prolonged progression-free survival and better intracranial activity compared with first-generation and second-generation EGFR TKIs. 1 , 2 , 3 Since these initial results, several phase 3 trials have explored novel, selective oral third-generation EGFR TKIs
The Lancet Respiratory Medicine , commentaire, 2022